Pieris Pharmaceuticals Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$194.3M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Pieris Pharmaceuticals's estimated annual revenue is currently $17.4M per year.(i)
  • Pieris Pharmaceuticals received $50.6M in venture funding in February 2018.
  • 0
  • Pieris Pharmaceuticals's total funding is $194.3M.

Employee Data

    00
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-94%N/AN/A
#2
$2.6M17N/AN/AN/A
#3
$6M39-20%$176.5MN/A
#4
$4.5M29N/AN/AN/A
#5
$2.6M17N/AN/AN/A
#6
N/A145-21%$39.5MN/A
#7
N/A0N/A$9.5MN/A
#8
$15.9M159-39%$135MN/A
#9
$1.7M1157%$20.9MN/A
#10
$2.8M1850%$28.9MN/A

Pieris Pharmaceuticals (NASDAQ: PIRS) is a clinical stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Pieris is listed on the NASDAQ and trades under the ticker symbol PIRS. Pieris is currently hiring in Boston and Freising, Germany. See here for our full list of job openings and information on applying: https://www.pieris.com/careers

keywords:Biotechnology,Healthcare,Pharmaceuticals

$194.3M

Total Funding

N/A

Number of Employees

$17.4M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

Pieris Pharmaceuticals News

2021-11-02 - Pieris Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

November 2, 2021 Pieris Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update Company To Host an Investor Conference Call on Tuesday, November 2, 2021 at 8:00 AM EDT Dosing completed in part 1a of phase 2a study of PRS-060/AZD1402 Dosing to begin this q ...

2021-11-08 - Pieris Pharmaceuticals and Servier Announce Dosing of First Patient in Phase 1/2 Trial of 4-1BB/PD-L1 Bispecific PRS-344/S095012

November 8, 2021 Pieris Pharmaceuticals and Servier Announce Dosing of First Patient in Phase 1/2 Trial of 4-1BB/PD-L1 Bispecific PRS- 344/S095012 BOSTON, MA and PARIS, FRANCE / ACCESSWIRE / November 8, 2021 /Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company a ...

2021-11-11 - Pieris Pharmaceuticals To Participate In Upcoming Investor Conferences

November 11, 2021 Pieris Pharmaceuticals To Participate In Upcoming Investor Conferences BOSTON, MA / ACCESSWIRE /November 11, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technolog ...

09/09/2019 - BNP Paribas Arbitrage SA Sells 4466 Shares of Pieris ...

BNP Paribas Arbitrage SA decreased its holdings in Pieris Pharmaceuticals Inc (NASDAQ:PIRS) by 41.3% during the 2nd quarter, according to ...

09/03/2019 - Pieris Pharmaceuticals Announces Changes to Senior ...

BOSTON, MA / ACCESSWIRE / September 3, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company ...

08/29/2019 - Pieris Pharmaceuticals to Participate in Upcoming Investor ...

About Pieris Pharmaceuticals: Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$77M0N/A$866M
#2
$7.4M0N/A$0.5M
#3
$5.5M0N/A$86.3M
#4
$66.9M0N/A$142M
#5
$26.4M0N/A$38M

Pieris Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2016-06-20$16.5MUndisclosedArticle
2018-02-22$50.6MUndisclosedArticle